Phil operates a software-driven commercialization platform that replaces traditional call-center hub models by streamlining workflows for patients, prescribers, pharmacies, insurers, and manufacturers. The platform has driven up to 6x higher adherence, 33% better affordability, and operates at roughly one-tenth the cost of traditional hubs. Phil targets the growing “specialty-lite” and retail therapy markets and emphasizes improving patient access and affordability. The company plans to accelerate integration of AI across its platform and expand customer deployments into new therapeutic areas. Financially, since its Series D in 2021 Phil has achieved over 10x prescription volume growth, finished 2024 with more than 150% year‑over‑year net revenue growth, and has become cash flow positive. The business emphasizes operational efficiency and scalable software-driven commercialization as its core differentiator. Phil is a San Francisco-based provider of therapy deployment software for the pharmaceutical market. Its platform enables manufacturers to control distribution channels by streamlining the complex, distributed workflow spanning patients, prescribers, pharmacies, insurers, and manufacturers. Led by founder and CEO Deepak Thomas, Phil focuses on simplifying and automating processes across stakeholders in the therapy delivery ecosystem. The company intends to use the Series D proceeds to accelerate product development while continuing to support customer growth. Phil raised $56M in a Series D financing as part of an arrangement with Warburg Pincus to invest up to $100M. Phil provides a prescription management software platform that connects patients, prescribers, pharmacies and manufacturers to lower systemic cost and improve patient outcomes. The platform connects over 36,000 prescribers in all major states with their patients and independent pharmacies across the nation. Led by founder and CEO Deepak Thomas, Phil focuses on specialty prescription drug distribution and management. The company closed a $25M Series B to support growth. Phil intends to use the funds to accelerate growth, hire technical talent and expand its geographic presence. The raise signals investor confidence in the company’s traction and product-market fit. Phil provides a concierge prescription management and delivery service that automates communication between doctors, insurers, pharmacy staff, and patients to ensure timely refills and free home delivery. The platform connects users with top-rated, community-based pharmacies and is NABP-certified. Phil works with dozens of partners and more than 8,000 doctors nationwide and, since November 2016, has grown to cover 95% of the U.S. population. Customer prescription volume doubled within Q1–Q2 and continues to accelerate. The company targets patients who take multiple daily medications and aims to reduce the substantial costs associated with poor drug adherence. Phil plans to expand its national network and scale operations to maintain service quality as volume grows.

Total raised

$151M

Funding rounds

4

Latest round

Debt Financing

Latest activity

Jul 2025